{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:06:13Z","timestamp":1777467973592,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BD"],"published-print":{"date-parts":[[2022,5,10]]},"abstract":"<jats:p>BACKGROUND: Around 5%\u201310% of breast cancers are due to hereditary breast and ovarian cancer syndrome. Genetic testing is important to identify these cases, enabling the adoption of specific risk-reducing treatment strategies. OBJECTIVE: To analyze the performance of genetic testing and its implications in patients with indication of genetic testing to identify hereditary predisposition to breast cancer. METHODS: This is a retrospective observational cross-sectional study, including 176 patients with clinical indication of genetic testing for pathogenic variants related to breast, ovarian and pancreatic cancers (among others), managed from 1999 to 2021 in an Oncology private clinic located in the city of Teresina (PI), Brazil. RESULTS: There was a predominance of female patients (98.9%) and those with a family (91.0%) and personal history (64.2%) of cancer. In the study, 102 patients (57.9%) received genetic testing. BRCA1 and BRCA2 pathogenic variants occurred in 26 cases (90%). Another three PALB2 and TP53 pathogenic variants were detected. Eleven pathogenic variant carriers (38%) underwent risk-reducing surgeries. CONCLUSIONS: BRCA1\/BRCA2 pathogenic variants occurred in around 25% of tested patients. Approximately 42.0% of the patients did not undergo genetic testing, despite clinical indication.<\/jats:p>","DOI":"10.3233\/bd-210082","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T12:17:44Z","timestamp":1652444264000},"page":"249-254","source":"Crossref","is-referenced-by-count":4,"title":["Genetic testing for hereditary predisposition to breast cancer in the real world: Initial experience"],"prefix":"10.1177","volume":"41","author":[{"given":"Danilo Rafael","family":"da Silva Fontinele","sequence":"first","affiliation":[{"name":"Health Science Center, State University of Piau\u00ed, , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Everton","family":"Assun\u00e7\u00e3o Ribeiro da Costa","sequence":"additional","affiliation":[{"name":"Health Science Center, State University of Piau\u00ed, , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Kamila","family":"da Silva Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"Health Science Center, State University of Piau\u00ed, , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabas Carlos","family":"Vieira","sequence":"additional","affiliation":[{"name":", Oncocenter, , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/BD-210082_ref1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10147-017-1208-9","article-title":"Management of hereditary breast and ovarian cancer","volume":"23","author":"Yamauchi","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.3233\/BD-210082_ref3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jama.2016.16918","article-title":"Genetic testing and counseling among patients with newly diagnosed breast cancer","volume":"317","author":"Kurian","year":"2017","journal-title":"JAMA"},{"key":"10.3233\/BD-210082_ref4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.3233\/BD-210082_ref7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1897-4287-12-8","article-title":"TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families","volume":"12","author":"Cury","year":"2014","journal-title":"Hered Cancer Clin Pract"},{"key":"10.3233\/BD-210082_ref8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.6004\/jnccn.2016.0018","article-title":"Genetic\/familial high-risk assessment: breast and ovarian, Version 2.2015","volume":"14","author":"Daly","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.3233\/BD-210082_ref9","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","article-title":"Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer","volume":"295","author":"Walsh","year":"2006","journal-title":"JAMA"},{"key":"10.3233\/BD-210082_ref10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1101\/gad.1770309","article-title":"NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control","volume":"23","author":"Wang","year":"2009","journal-title":"Genes Dev"},{"key":"10.3233\/BD-210082_ref11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.3233\/BD-210082_ref13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","article-title":"Clinical implications of germline mutations in breast cancer: TP53","volume":"167","author":"Schon","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.3233\/BD-210082_ref14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1399-0004.2012.01859.x","article-title":"Familial breast cancer","volume":"82","author":"Lalloo","year":"2012","journal-title":"Clin Genet"},{"key":"10.3233\/BD-210082_ref15","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","volume":"136","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"Int J Cancer"},{"key":"10.3233\/BD-210082_ref16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jmig.2017.03.001","article-title":"The role of routine peritoneal and omental biopsies at risk-reducing salpingo-oophorectomy","volume":"24","author":"Miller","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"10.3233\/BD-210082_ref17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.3233\/BD-210082_ref18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1634\/theoncologist.2016-0444","article-title":"Risk-reducing strategies for ovarian cancer in BRCA mutation carriers: a balancing act","volume":"22","author":"Tschernichovsky","year":"2017","journal-title":"Oncologist"}],"container-title":["Breast Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/BD-210082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:32:25Z","timestamp":1777383145000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/BD-210082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":14,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/bd-210082","relation":{},"ISSN":["0888-6008","1558-1551"],"issn-type":[{"value":"0888-6008","type":"print"},{"value":"1558-1551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]}}}